JBIO — Jade Biosciences, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1798749 ·
Last close
$15.40
Market Cap
$979.40M
52W High
$28.00
52W Low
$11.02
ADV30
954,942
Next earnings
2026-11-13
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -39,640,000 -35,055,000 486,391,000 80,386,000 30,887,000
Jun 2026 0 — -58,916,000 -55,765,000 472,113,000 107,250,000 32,198,000
Mar 2026 0 — -43,445,000 -40,368,000 319,433,000 55,085,000 22,971,000
Dec 2025 0 — -34,979,000 -31,932,000 349,781,000 88,438,000 17,263,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-123,510,000
Investing CF
$-352,972,000
Financing CF
$362,888,000
CapEx
$-60,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.67
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-270,522,000
Inventory
—
Receivables
—
ST Investments
$353,955,000
EBIT TTM
$-164,741,000
Pretax Income TTM
$-153,151,000
Interest Exp TTM
—
Analysts
8

Annual Trend (SEC EDGAR, last 2y)

Revenues vs Net Income (last 2y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -113,542,000 -127,410,000 349,781,000 17,263,000 332,518,000 -94,689,000
Dec 2024 — — — 72,799,000 119,598,000 -46,799,000 —

TTM Snapshot

Revenues TTM
$0
NetIncome TTM
$-188,891,000
OpCashFlow TTM
—
Assets (Latest)
$472,113,000
Forward EPS
$-2.26

Max Pain — expiry 2027-02-19 (volume-derived — Yahoo OI feed degraded)

max pain strike: $20.00 · spot: $15.49 · call volume: 5 · put volume: 1

Peers — same industry

TickerNameMarket CapLastDaily %
SPTX Seaport Therapeutics, Inc. $972.65M $18.17 —
SVRA Savara Inc $988.39M $4.48 —
ANRO Alto Neuroscience, Inc. $999.16M $24.91 —
CYRX Cryoport, Inc. $999.81M $19.74 —
MLTX MoonLake Immunotherapeutics $957.45M $11.25 —

News headlines (Yahoo Finance, 1h cache)

Jade Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Update
2026-11-13 12:00 · Yahoo
Jade Biosciences to Participate in Upcoming Conferences
2026-11-03 12:00 · Yahoo
Jade Biosciences to Highlight Advancement of JADE101 Development Program at American Society of Nephrology (ASN) Kidney Week 2026
2026-10-21 11:00 · Yahoo
Jade Biosciences Announces Preclinical Data Characterizing JADE301, a Potentially Best-in-Class, Half-Life-Extended Anti-IFN-β Monoclonal Antibody in Development for Dermatomyositis, at EADV 2026
2026-09-30 11:00 · Yahoo
Is Jade Biosciences, Inc. (JBIO) Stock a Rising Biotech Opportunity in the $20B IgA Nephropathy Market?
2026-06-30 13:21 · Yahoo
Jade Biosciences Announces Appointment of Mark Eisner, M.D., M.P.H., to Board of Directors
2026-06-26 11:00 · Yahoo
Jade Biosciences Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
2026-06-05 20:01 · Yahoo
Jade Biosciences Announces Pricing of Public Offering of Common Stock
2026-06-04 02:58 · Yahoo
Jade Biosciences Announces Positive Interim Phase 1 Results for JADE101 Demonstrating Potential Best-in-Class Profile and Every-12-Week Dosing in IgA Nephropathy
2026-06-01 11:00 · Yahoo
Jade Biosciences’ JADE101 Delivers Deep IgA Cuts, Clearing Path for Kidney Trials
2026-06-02 01:07 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.